Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Stock analysts at Cantor Fitzgerald increased their FY2017 earnings per share estimates for shares of Intercept Pharmaceuticals in a research note issued on Sunday. Cantor Fitzgerald analyst E. Piros now forecasts that the biopharmaceutical company will earn ($13.30) per share for the year, up from their previous estimate of ($13.95). Cantor Fitzgerald has a “Neutral” rating and a $69.00 price target on the stock. Cantor Fitzgerald also issued estimates for Intercept Pharmaceuticals’ FY2018 earnings at ($13.50) EPS.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.48) by $0.59. The business had revenue of $41.33 million for the quarter, compared to analysts’ expectations of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The business’s quarterly revenue was up 697.9% on a year-over-year basis. During the same period last year, the firm earned ($3.59) earnings per share.
ILLEGAL ACTIVITY NOTICE: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2017/11/09/cantor-fitzgerald-brokers-raise-earnings-estimates-for-intercept-pharmaceuticals-inc-icpt.html.
A number of other brokerages have also weighed in on ICPT. Wedbush restated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. Jefferies Group LLC restated a “buy” rating and set a $275.00 price objective on shares of Intercept Pharmaceuticals in a research report on Sunday, July 30th. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. ValuEngine upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $200.00 price objective on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 1st. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $153.76.
Intercept Pharmaceuticals (NASDAQ ICPT) opened at $64.47 on Wednesday. The company has a current ratio of 5.95, a quick ratio of 6.61 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a 12-month low of $54.98 and a 12-month high of $135.59.
Institutional investors have recently bought and sold shares of the company. Sphera Funds Management LTD. raised its stake in shares of Intercept Pharmaceuticals by 100.0% during the second quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $3,632,000 after acquiring an additional 15,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after acquiring an additional 57,149 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its stake in shares of Intercept Pharmaceuticals by 85.6% during the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock valued at $824,000 after acquiring an additional 3,136 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Intercept Pharmaceuticals by 12.8% during the first quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock valued at $16,301,000 after acquiring an additional 16,392 shares in the last quarter. Finally, Asymmetry Capital Management L.P. bought a new stake in shares of Intercept Pharmaceuticals during the second quarter valued at approximately $3,580,000. 82.69% of the stock is owned by hedge funds and other institutional investors.
In other news, insider Lisa Bright sold 253 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $111.31, for a total transaction of $28,161.43. Following the completion of the sale, the insider now owns 23,324 shares of the company’s stock, valued at $2,596,194.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO David Shapiro sold 1,250 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $117.43, for a total transaction of $146,787.50. Following the sale, the chief marketing officer now directly owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. In the last three months, insiders sold 4,069 shares of company stock valued at $325,974. 9.20% of the stock is owned by insiders.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.